Welcome to our dedicated page for Trinity Capital news (Ticker: TRIN), a resource for investors and traders seeking the latest updates and insights on Trinity Capital stock.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager focused on private credit, with a portfolio built around secured loans, equipment financings, and related investments in growth-oriented companies. The TRIN news feed on Stock Titan aggregates company-issued press releases, portfolio updates, and financial announcements that reflect how this strategy is being executed over time.
News coverage for Trinity Capital frequently includes quarterly and annual financial results, portfolio activity summaries, and details on new credit facilities or capital markets transactions. For example, the company issues updates on total investment income, net investment income, net asset value, and the composition and risk ratings of its investment portfolio. It also reports on changes to its borrowing arrangements, such as new or expanded credit facilities and term loan agreements with institutional lenders.
Another major component of TRIN news involves transaction announcements with portfolio companies. Trinity Capital regularly discloses commitments of growth capital and equipment financing to businesses in sectors such as life sciences, technology, financial technology, recycling and materials, and consumer products. These releases describe the purpose of the financing and how it supports the counterparties’ expansion, commercialization, or operational scaling plans, while illustrating the application of Trinity Capital’s lending verticals, including Tech Lending, Life Sciences, Asset Based Lending, and Equipment Finance.
Dividend declarations and distribution policies are also recurring topics. Trinity Capital provides information on regular cash dividends, changes in payment frequency, and its intention to distribute a high percentage of taxable income to maintain regulated investment company status. Investors and analysts can use the TRIN news page to follow these developments, track origination and funding volumes, and review management’s commentary on portfolio performance and market opportunities.
Trinity Capital (Nasdaq: TRIN) committed $50 million in a debt term loan to Sage Health on March 27, 2026 to support expansion of senior-focused primary care and wellness centers in medically underserved areas. The financing brings Sage's total capital raised to $170 million.
Sage limits physicians to 500 patients each, operates in primary-care shortage neighborhoods, and integrates primary care, wellness, and care coordination to manage chronic conditions. Armentum Partners served as Sage's debt capital advisor.
Trinity Capital (Nasdaq: TRIN) declared a monthly regular dividend of $0.17 per share for April, May and June 2026.
Declaration date for all three payments was March 18, 2026; record dates are April 15, May 15 and June 11, 2026, with payment dates April 30, May 29 and June 30, 2026. The company said it targets distributing roughly 90%–100% of taxable quarterly income to maintain RIC tax treatment.
Capital Southwest (Nasdaq: CSWC) and Trinity Capital (Nasdaq: TRIN) formed a 50/50 joint venture on March 16, 2026 to invest primarily in first-out senior secured debt in the lower middle market. Each partner committed $50 million, creating initial equity of $100 million, and the JV plans to use a senior-secured credit facility to obtain leverage for portfolio investments.
The JV's board of managers will have equal representation from both firms, and investment and operational decisions will be overseen jointly.
Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Monteris Medical to support commercialization of the NeuroBlate System and expansion of clinical research programs. The NeuroBlate System is an MRI-guided, robotically controlled laser interstitial thermal therapy platform for brain tumors, radiation necrosis, and drug-resistant epilepsy.
The financing complements Monteris' Series E equity support and is intended to accelerate commercial expansion, product innovation, and clinical adoption at neuroscience centers.
Trinity Capital (Nasdaq: TRIN) committed $20 million in growth capital to Emboline to support commercial preparation for the Emboliner embolic protection catheter. The Emboliner uses a flexible mesh to capture and remove debris during minimally invasive heart procedures.
Emboline completed patient enrollment in the PROTECT H2H IDE clinical trial; funds will scale manufacturing, expand the team, and support clinical and regulatory milestones ahead of commercial launch.
Emboline closed $20 million in growth capital from Trinity Capital (Nasdaq: TRIN) to fund commercialization of the Emboliner® Embolic Protection System and further platform development. The company completed enrollment in its IDE trial (NCT05684146) and will present results on March 29, 2026 at ACC.
Financing will support U.S. and European commercial launch preparations and ongoing regulatory submissions; the Emboliner device remains investigational and is not available for commercial sale.
Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Neuros Medical on March 10, 2026 to scale commercialization of the FDA-approved Altius Direct Electrical Nerve Stimulation System.
The funding is intended to expand market access for a non-opioid neuromodulation therapy for post-amputation phantom and residual limb pain and provide additional financial flexibility under Neuros Medical's debt facility.
Trinity Capital (Nasdaq: TRIN) committed $50 million in growth capital to Dwelly on February 26, 2026 to scale the UK property-management marketplace.
The facility will fund Dwelly’s AI-driven roll-up strategy, supporting strategic acquisitions and platform expansion after crossing 10,000 properties under management, placing Dwelly among the UK’s top 15 letting agencies.
Trinity Capital (Nasdaq: TRIN) reported record 2025 results with total investment income of $293.7M (+23.5% YoY) and record annual net investment income of $144.1M (or $2.08 per share).
NAV rose 32.9% YoY to $13.42 per share, platform AUM grew 38.2% to $2.8B, and total gross investments funded were $1.5B (+21.3% YoY). The company announced a transition to monthly dividends beginning January 2026.
Trinity Capital (Nasdaq: TRIN) released preliminary estimates for the quarter and year ended December 31, 2025. Q4 2025 net investment income is estimated at $0.51 to $0.53 per share. Estimated NAV is $13.36 to $13.44 per share. Non-accrual investments were approximately 0.7% of debt investments at fair value and 0.9% at cost as of December 31, 2025. Trinity Capital will host a conference call on February 25, 2026 at 12:00 p.m. ET with a replay available through March 4, 2026.